Progression-free survival 6 months [clinicaltrials_resource:04a0b20725d8639333612e914b35587b]
Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Progression-free survival 6 months [clinicaltrials_resource:04a0b20725d8639333612e914b35587b]
Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Bio2RDF identifier
04a0b20725d8639333612e914b35587b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:04a0b20725d8639333612e914b35587b
measure [clinicaltrials_vocabulary:measure]
Progression-free survival
time frame [clinicaltrials_vocabulary:time-frame]
description
Patients receive oral pazopani ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:04a0b20725d8639333612e914b35587b
title
Progression-free survival 6 months
@en
type
label
Progression-free survival 6 mo ...... 0b20725d8639333612e914b35587b]
@en